The U.S. Food and Drug Administration announced it has approved Linzess capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation. Linzess is the first treatment approved for IBS-C in pediatric patients, the FDA noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: